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Abstract
This review is concerned with the psychosocial functioning and the quality
of life in patients with pituitary insufficiency who are receiving conventional
hormone replacement therapy. The possible negative effects of pituitary sur-
gery, treatment with irradiation, and suboptimal replacement regimens with
hormones other than growth hormone on mood, behaviour and cognitive
functioning are discussed. The influence of growth hormone deficiency per
se, and the outcome of growth hormone therapy in adult patients are addressed
in detail. A possible mechanism for a direct effect of growth hormone on the
brain is presented.
.......................
Introduction of these were found to be living as singles compared
with short normal controls, and on average they had less
prestigious jobs and a lower income [4].Experienced clinicians have long had the impression
that patients with pituitary insufficiency have a dimin- Although it seems clear that, as a group, patients with
pituitary insufficiency of childhood onset are socially disad-ished overall capacity even when they are receiving ade-
quate conventional hormone replacement therapy, i.e. vantaged with respect to their living situation, partnership
and career development, the relative impacts of inadequatethyroxine and adrenal and sex steroids. This impression
is supported by reports on reduced psychosocial func- hormone replacement therapy, a chronic disease during
childhood and adolescence, late sexual maturation and thetioning in young adults with childhood-onset (CO) pitu-
itary insufficiency who were treated with growth hormone effects of a short stature per se remain to be clarified. The
hypothesis that GH in itself may be an important determi-(GH) until they had reached their final height [1–4]. In
a study of 116 patients of ages 18–38 years, the rate of nant of psychosocial functioning is supported by the finding
of similar functioning in young patients with isolated GHDunemployment was found to be approximately 3 times
higher than expected and the percentage number married and those with multiple hormone deficiencies [4].
less than 30% of the expected [1]. Further, a higher pro-
portion than expected were living at home with their
parents, and were lacking a driver’s licence. There was no Quality of Life and Cognitive Function in
Patients with Pituitary Diseasedifference between patients with organic and idiopathic
causes of the disease. In a recent study of 210 young
adults with growth hormone deficiency (GHD) who had A few studies have indicated that adult patients with
pituitary insufficiency are psychologically compromisedbeen treated with GH in childhood, a higher proportion
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Table 1. Reduced quality of life in patients with pituitary insufficiency as assessed by various questionnaires
Author Ref. M/F Mean age Questionnaires
n years
NHP PGWB GHQ HSCL POMS STAI Sjo¨berg
total energy emotions social
score isolation
McGauley, 1989 5 16/8 39 yes yes yes yes yes yes – – – –
Degerblad et al., 1990 16 3/3 20 – – – – noa – noa
Whitehead et al., 1992 17 9/5 29 ? noa – – – – –
Rose´n et al., 1994 6 51/35 55 yes yes trend yes – – – – – –
Burman et al., 1995 7 21/15 46 yes yes yes no yesa – yes – – –
Deijen et al., 1996 8 46/0 26 – – – no yesb yesb –
a Comparisons were made with normative data in the literature.
b Lower vigor (POMS) and higher state anxiety (STAI) were found only in patients with multiple hormone deficiencies.
[5–8]. In most of these studies the disease in the majority
of the patients had developed in adult years [5–7]. In
general, information on the quality of life has been
obtained from questionnaires from which the patients’
perception of their well-being and ability to cope with
daily life activities has been compared with that of a
reference population. The two most commonly used
questionnaires in this group of patients are the Not-
tingham Health Profile (NHP) [9] and the Psychological
General Well-Being index (PGWB) [10]. Other instru-
ments such as the Hopkins Symptom Checklist (HSCL)
[11], the Profile of Mood States (POMS) [12] and the
State-Trait Anxiety Inventory (STAI) [13, 14] have pro-
vided additional information. A lack of energy and
emotional problems are the two most consistent findings
(table 1, fig. 1). In one of the studies a tendency to a
] ] ]
] ]
higher rate of disability pensions was observed, indicat-
Fig. 1. Baseline data (mean×SEM) for the six dimensions of theing a reduced capacity for work [6]. In another study
NHP in 36 adults with GHD. For comparison, scores of a healthyhypopituitarism was found to be associated with an
control group controlled for age and sex are given. ***p=0.001;
increased psychiatric morbidity, depression and dysthy- **p=0.01. (Reproduced from [7] with the permission of the publisher.)
mia, when comparison was made with a group of pa-
tients with diabetes mellitus [15].
with GHD of recent onset tend to be better off than thoseHowever, in some series of patients [16, 17], absence
with disease of long-standing duration [7].of negative effects on the quality of life has been reported
Present knowledge about the impact of pituitary in-(table 1). The lack of total conformity between study
sufficiency on cognitive function is limited. This is duefindings is not unexpected given the relatively small num-
to a lack of uniformity in the psychological tests usedbers of patients investigated in each study, the variety of
and to the absence of relevant control groups in someinstruments used and the heterogeneity of the patient
studies. In addition, the effects of treatment for pituitarymaterials. For instance, both gender and the duration of
tumours and the effects of the tumour growth in itselfthe disease have been found to influence the perception
can be difficult to separate from the impact of inadequateof the quality of life. Women with pituitary deficiency
hormone replacement.tend to report more problems than men, and patients
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Cognitive Function in Short-Statured Normal
Children versus Children with GHD
Patients with CO pituitary insufficiency have, in the
past at least, often not attained a normal height and
this might be of relevance for their cognitive function.
Academic underachievement and cognitive failure may be
encountered in children with short stature of an idiopathic
origin (ISS), despite average intelligence and unimpaired
self-esteem. For instance, poor concentration, hyperactiv-
]
]
]
]
ity, lower attainment in reading and thought problems
have been observed in such children [18, 19]. Fig. 2. Iconic and short-term memory scores (mean×SE) in
Several studies have found that children with idio- IGHD (rectangle shaded with dots) and MPHD adults (rectangle
pathic GH deficiency (IGHD), with multiple pituitary shaded with lines), compared with age- and sex-matched controls
(solid rectangle); * p=0.05: patients versus controls [reprinted fromhormone deficiencies (MPHD) and with ISS showed de-
8, with kind permission from Elsevier, Kidlington, UK].layed school achievements and a discrepancy between IQ
and achievement scores in reading, spelling and arith-
metic [20–22]. Steinhausen and Stahnke [23] found no
differences in verbal comprehensiveness, reasoning, word memory components and showed a lower IQ score than
did age-matched healthy controls (fig. 2). In addition, thefluency and spatial orientation in young patients with
IGHD, MPHD and healthy controls with short stature. IQ score and the education level in the patient group
tended to be positively correlated with serum IGF-I con-From these findings it may be concluded that GHD has
no impact on psychological function and that the dys- centration, suggesting that subnormal cognitive func-
tioning is specifically related to GHD. Similar results havefunctioning of short-statured individuals is mainly the
result of experiences associated with the small stature. been found in a study by Burman et al. [7], in which
patients with AO GHD reported significantly more prob-However, other authors suggest that not only short stature
per se, but also the neurological sequelae of long-term lems with their cognitive function, particularly concentra-
tion ability as assessed by the HSCL, than did the healthyGHD may be responsible for the development of specific
learning disabilities. This notion is based on the finding reference group. These studies suggest that patients with
CO GHD and those with AO GHD exhibit subnormalthat children with MPHD and IGHD, but not those with
ISS, show disturbances in visual-motor integration [24]. cognitive function which may be caused by the effects of
GHD on brain development or neural cell metabolism.
Cognitive Function in Adults with GHD
Patients with adult onset (AO) GHD frequently report Effects of Treatment for Pituitary Tumours
The aetiology of the disease and the treatment of thelapses of memory, difficulty in concentrating, and forget-
fulness [25–27]. However, as a group young adults with precipitating disorder, i.e. medication, surgery and/or ra-
diotherapy, are likely to influence the mental performanceCO GHD have been found to have a normal IQ score and
a good educational achievement, although differences in and well-being. This issue has been addressed in two
recent studies [29, 30]. In one of them the self-reportedcognitive functions have been observed between patients
with IGHD and MPHD. According to the findings by psychosocial functioning of 48 patients who had been
treated with transsphenoidal surgery for nonfunctioningGalatzer et al. [28], the distribution of IQ scores of pa-
tients with IGHD is in the upper part of the curve, while pituitary tumours was compared with that of 42 patients
who had undergone mastoid surgery, and no differencesthat of patients with MPHD is skewed towards the lower
part. This may indicate that a combined deficiency of were found [29]. A noteworthy observation was that the
subgroup of hypopituitary patients who in addition topituitary hormones during the critical period of brain
development may be more harmful than that due to GHD surgery had received radiotherapy reported problems
with their mental health and overall quality of life. Analone.
By contrast, cognitive dysfunction has been equally analysis of subscores showed that this was mainly ex-
plained by an increased prevalence of depression andfound in IGHD and MPHD patients with CO GHD
[8]. Patients with IGHD and those with MPHD both decreased control of emotions. The results suggest that
conventional radiotherapy has a deleterious impact ondemonstrated lower performance with respect to several
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the brain function, however, but does not favour the idea with respect to problem-solving, memory, sustained at-
tention, complex perceptual tracking and manual dexter-of a lack of GH as a major determinant of this effect. It
should be emphasized that the mean age of these patients ity [37]. A study by Lee et al. [38] showed lower scores
for verbal performance, IQ, delayed visual memory, andwas 59 years. The negative effects of reduced energy and
vitality are likely to be less apparent in individuals who immediate verbal memory of patients who had received
CRT 2, 5–10 years previously.have retired from work.
Lack of energy, mild mood disturbances and decreased A more recent study on cognitive function following
CRT in adult patients made use of extensive neuropsycho-self-perceived social adjustment have been observed in
patients treated for pituitary tumours with either medica- logical measurements [39]. Transient cognitive dysfunc-
tion affecting mainly attentional processes was observedtion or surgery, except in the group of patients who had
been operated on with a transfrontal approach [30]. In at 6 months after limited-field CRT and disappeared at
12 months after CRT. No other cognitive impairmentscontrast, all groups of patients were considered by a close
informant to exhibit impaired social adjustment. This in the entire group were found over a 48-month follow-
up period.indicates that frontal surgery is associated with under-
reporting of difficulties, probably due to a lack of insight. In a study of adult patients with pituitary tumours
neuropsychological assessment revealed impairment ofAn unrealistic self-appraisal of cognitive and behavioural
impairment has previously been observed in patients with verbal and visual memory and executive function [40].
This did not appear to be related to the size of the tumourfrontal brain damage following head injuries [31]. In the
subgroup of patients who in addition to transsphenoidal or the effects of radiotherapy or surgery. The authors
suggested that a disturbance of neurotransmission or neu-surgery had received radiotherapy, fewer problems with
depression and social adjustment were reported than in romodulation at the level of the hypothalamic micro-
environment could possibly explain the poor test results.the group treated with surgery only [30].
Irradiation-induced cognitive dysfunction may be due
to damage to the hypothalamus, resulting in personalityIrradiation Effects in Children
Cousens et al. [32], who conducted a meta-analysis on changes and impairment of cognitive capabilities such as
reduced attention span, memory loss and reasoning abil-30 studies of childhood leukaemia assessing the effects
of central nervous system prophylactic treatment, which ity [41]. Another possibility is that irradiation-induced
vascular injury is followed by ischaemia and hypoxia inincludes cranial irradiation therapy (CRT), on intelli-
gence, concluded that childhood leukaemia appears to the hippocampal region in particular, which may be re-
sponsible for memory impairment [42]. Consistent withbe associated with decrements in intelligence which are
a function of both psychosocial factors and the treatment. this notion is the finding that conventional CRT in rats
impairs memory function, which was accompanied by aIn a more recent review on the neuropsychological
effects of central nervous system prophylactic treatment reduction in regional glucose metabolism in the frontal
cortex of the radiated rats [43].in childhood leukaemia [33], 25 studies are cited that
report negative effects of irradiation on cognitive mea- Although the underlying mechanisms of irradiation-
induced neurocognitive dysfunction are not yet fully un-surements. Other studies indicate that children who re-
ceive CRT develop impaired visual and verbal memory, derstood, present evidence indicates that CRT may induce
neurocognitive dysfunction, younger children being theattention capacity, verbal fluency, and visual discrimina-
tion skills, verbal IQ, and reading and spelling [34, 35]. most susceptible to these injuries. An exact threshold dose
after which negative effects occur cannot be given. DiffuseThere is therefore substantial evidence that CRT may
have a deleterious effect on cognitive abilities in children, radiation-induced injury to the brain that does not result
in a localized necrotizing lesion may still induce neuro-the most significant cognitive decline occurring in chil-
dren less than 7 years of age [36]. psychological deficits. These deficits may be present in
the absence of overt necrosis, even without identifying
abnormal neural imaging [36].Irradiation Effects in Adults
A review of the neurobehavioural effects of irradiation
in adults includes 18 studies of prophylactic CRT [36]. Influence of Inadequate Replacement with Thyroxine,
Adrenal and Sex SteroidsAlthough a large number of these studies reported behavi-
oural changes, few made use of sensitive neuropsycho- Psychiatric signs such as depression and anxiety are
common in endocrine disorders [44]. Hormones maylogical measures. One of these studies found impairments
157Quality of Life and Cognitive Function Psychother Psychosom 1998;67:154–167
affect brain function through direct effects on the course affective behaviour. Indeed, testosterone has been found
to be associated with dominance and aggression-relatedof early brain development. These effects are permanent.
In addition, hormones may temporarily affect behaviour behaviour [53]. Higher testosterone concentrations were
found to be associated with more ‘masculine’ attributesthrough their impact on both peripheral and neural-based
processes [45]. MPHD is characterized by deficiencies in a in females, such as enterprise, resourcefulness, uninhib-
itedness and impulsiveness [54]. Testosterone concentra-number of hormones other than GH, such as sex steroids,
ACTH/adrenal steroids and thyroxine. Patients with tions have also been found to be positively correlated
with disinhibition, or the tendency to display high levelsMPHD therefore receive hormonal replacement therapy
with one or more of these hormones. However, this re- of sensation-seeking behaviour [55]. Men with very low
concentrations of testosterone exhibit more passivenessplacement may not be instituted in time to children with
MPHD, or it may be suboptimal, with negative effects and dependency than do those with average concentra-
tions [56]. Administration of testosterone to hypogonadalon brain function.
In adult patients with hormone deficiencies the con- men has been accompanied with beneficial effects on sev-
eral parameters of mood and energy [57]. In patients withventional regimens today may not be as appropriate as
they were previously thought, particularly with respect MPHD, state anxiety was found to be inversely related
to serum testosterone. This finding was attributed to theto adrenal steroids and sex hormones. For instance, many
patients with secondary hypoadrenalism are frequently hypogonadal appearance of these patients [8].
Concentrations of oestrogen, whether alone or in rela-given a standard dose of cortisone acetate of 37.5 mg or
higher, even though current knowledge indicates that a tion to other hormones such as progesterone or testoster-
one, may also be related to aggression. Low concentra-lower dose is sufficient in a majority of cases. In view of
the interindividual variation of the sensitivity to cortico- tions of oestrogen and progesterone occurring premen-
strually have been associated with aggression-like behav-steroids, it is probable that a proportion of the patients
might experience negative emotional effects, such as anxi- iour such as competitiveness, irritability, tension and
mood swings. Among elderly men, higher androgen/oes-ety and nervousness, on the too high conventional doses.
On the other hand, a deficiency of ACTH and/or the trogen ratios were related to higher self-ratings of irritabil-
ity and aggression. From these and other observations,concomitant cortisol deficiency may be associated with
reduced energy, arousal and cognitive functioning. Adult the general conclusion has been drawn that sex steroids
(testosterone and estradiol) have activating effects on thepatients with ACTH deficiency show depressive symp-
toms and apathy [46], coma, anorexia, weight loss, nervous system. Oestrogens have been shown to increase
the dopamine receptor density in the striatum, as well asnausea, headache and seizures [47, 48]. Weakness and
loss of energy in ACTH deficiency are also reported in hydroxytryptamine 2A binding sites in areas of the brain
concerned with the control of mood, cognition and emo-some cases [49, 50]. Treatment with ACTH has been
found to enhance arousal, vigilance, motivation and se- tions [58]. In a recent controlled study, testosterone and
oestrogen administered in physiological doses to patientslective attention [51]. Visual attention and the associated
motor responses have also been found to improve when with pubertal delay were found to increase self-reported
aggressive behaviour in boys and girls, respectively [59].ACTH levels were raised [52]. In MPHD patients, the
observed subnormal perceptual-motor skills were attri- Moderate concentrations of oestradiol have been associ-
ated with positive effects on mood and behaviour, whereasbuted to ACTH deficiency on the basis of the inverse
correlation between hydrocortisone replacement dose and a lack of oestradiol is tied to depression and emotional
lability. Overly high concentrations of sex steroids maythe quality of perceptual-motor performance [8].
The present modes of administration of sex steroids result in negative symptoms such as anxiety and depres-
sion [45].are not physiological in either men or women. In addition,
the views of physicians on the benefits of replacement GHD may also be accompanied by a deficiency of
thyroxine. As thyroid hyper- and hypofunction has beenwith sex hormones in women who are past the child-
bearing age vary considerably. Besides affecting sexual found to be associated with mental disturbances, sub-
optimal replacement with thyroxine may cause mooddrive and arousal, sex steroids may influence other aspects
of behaviour. changes. Higher scores on obsessive-compulsive and at-
tention-deficit symptoms have been related to lower con-With regard to testosterone, receptors are localized in
the hypothalamus, amygdala, septal nucleus and hippo- centrations of FT4 [60]. In addition, adjunctive treatment
with T4 reduced the amplitude and frequency of maniccampus [45], regions that are involved in mood and
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Table 2. Placebo-controlled studies of the quality of life in adults with GHD
Author Ref. n Age Design Tests Outcome
Degerblad et al., 1990 16 6 20–38 12 weeks cross-over 2 self-reported mood scales NS
5 psychometric tests NS
McGauley, 1989 5 23 21–55 6 months placebo vs. drug NHP *
PGWP total NS
mood *
Whitehead et al., 1992 17 10 19–52 6 months cross-over NHP NS
PGWB NS
Bengtsson et al., 1993 65 9 34–58 6 months cross-over SCL-90 NS
CPRS *
Ma˚rdh et al., 1994 66 125 20–60 6 months placebo vs. NHP total score NS
drug+6 months open energy *
PGWB total *
vitality *
Beshyah et al., 1995 67 38 19–67 6 months placebo vs. drug GHQ *a
CPRS NS
Spontaneous patients reports *
Burman et al., 1995 7 36 28–57 9 months cross-over NHP NSb
HSCL trend
(p>0.06)
PGWP NS
Partner questionnaire *
Deijen et al., 1996 8 46 19–37 26 weeks placebo vs. drug HSCL NS
POMS NS
STAI NS
Cognitive function *
*Difference between GH and placebo statistically significant. NS>not significant.
a The effects on the quality of life were better after treatment with placebo than after treatment with GH.
b p>0.03 when the effects of GH were assessed only in patients with baseline scores above zero (n>30).
and depressive phases in manic-depressive patients [61]. dose of hydrocortisone may reduce energy, and either too
low or too high a dose of thyroxine may cause depressiveIn contrast, elevated T4 levels have been found in de-
pressed and manic patients, indicating that a higher level disturbances.
of thyroxine may be associated with major depressive
disorders [62]. Thyroxine levels have also been correlated
with psychopathology in hyperthyroid outpatients [63]. GH – Effects on Quality of Life
From the data available on the relation between thyroxine
and mental functioning, it may be concluded that low as The finding of a suboptimal quality of life in patients
with pituitary insufficiency has raised the question as towell as high concentrations of thyroxine may be associated
with depressive illness, whereas high concentrations seem what extent this can be accounted for by lack of GH.
This issue has been addressed in a few placebo-controlledto be particularly related to manic disease. Indeed, thyrox-
ine has been identified as belonging to a class of drugs studies [5, 7, 8, 16, 17, 65–67]. In general the numbers
of patients included have been small, and the treatmentwhich are probably capable of inducing mania in patients
predisposed to mood disorder [64]. periods have been limited (table 2). Only one of the studies
[8] has included sufficient numbers of patients with IGHDThe above data indicate that replacement with an inad-
equate dose of testosterone may result in passiveness, vs. MPHD to allow a separate evaluation of the treatment
effect.dependency and state anxiety, whereas too high a dose
may result in aggressive and dominant behaviour. Sub- Degerblad et al. [16] investigated young adults with
CO-GHD. A positive effect of GH therapy was experi-optimal replacement with female sex steroids may nega-
tively affect mood and emotions. In addition, too low a enced by some of the patients, but was not confirmed in
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Table 3. Responses to the partner’s questionnaire completed attwo mood scales and five psychometric tests. In two stud-
the end of the 21-month cross-over trial with human recombinant GHies on small numbers of patients, 6 months of GH therapy
and placebo in 36 adult patients with GHDwas compared with placebo treatment in a cross-over
design, with variable results [17, 65]. In one of the studies,
7 of 9 patients showed improvement when assessed by an
interviewer with use of the Comprehensive Psychological
Placebo GH p=
% %
More alert 0.0 69.0 0.0001Rating Scale, but no positive effects were found with use
More active 3.7 51.8 0.001
of the Symptom Checklist-90 inventory [65]. In another Higher endurance 3.6 60.7 0.0001
two studies where the quality of life of adult GHD pa- Less easily annoyed 7.1 28.6 0.10
Less worried 6.9 37.9 0.05tients was found to be poorer than that of reference popu-
More extrovert 3.4 37.9 0.01lations, a beneficial effect of GH was found after 6 [5]
More industrious 3.3 46.7 0.001and 9 months [7], respectively. McGauley et al. [5] re-
More happy 11.1 48.1 0.01
ported that treatment with GH was associated with a Better looks 10.3 51.7 0.01
positive effect on the overall score of NHP, and on a More satisfied with his/her occupation 7.7 34.6 0.05
Fewer family conflicts 3.4 24.1 0.10subscale assessing mood in the PGWB index. In the
Better personal relationships 3.4 34.5 0.01Uppsala trial [7] the effects on the quality of life were
documented by the use of three validated self-rating tests
The values indicate the percentages of yes responses to the different
and by a partner questionnaire. The most pronounced short questions. Significance was evaluated by the v2 test.
improvements after GH therapy consistently occurred in With permission [7].
areas that were particularly problematic at baseline, i.e.
energy, emotions and cognitive functions. The difference
between drug and placebo was close to being statistically
significant when assessed with the HSCL (p>0.06) and esteem, before treatment. This could indicate that hor-
mones other than GH are of major importance for moodthe NHP (p>0.08).
A limitation with the NHP is that the scores tend to and behaviour. As a group these patients had a hypogona-
dal appearance and reduced testosterone levels. However,be skewed towards low values both in general populations
[68] and in patients with diseases [69]. In the Uppsala since the severity of the GHD, as assessed by serum
insulin-like growth factor (IGF)-I, was less pronouncedtrial 6 of 36 patients had a baseline problem score of
zero, leaving no room for improvement. When the effect in the patients with isolated GHD than in those with
MPHD, direct comparisons between the two groups canwas evaluated after exclusion of these 6 patients, so that
the comparison was made only in patients with problems be difficult. In the same series of patients the presence of
abnormal lipid levels was found to be inversely relatedat baseline, the difference between GH and placebo be-
came statistically significant (p>0.03). We speculated to serum IGF-I [70]. However, it is worthy of note that
the observed deviations in vigour and anxiety were notthat a family member would be less likely to be subject
to a placebo effect and would be more objective than the corrected by GH [8], which could indicate either that
inadequately treated hormone deficiencies other thanpatients in evaluating effects on behaviour. Indeed the
partners observed marked effects after treatment with GHD, or structural brain damage, or a combination of
the two was of relatively greater importance in this groupGH but not after placebo (table 3).
In a large European multicentre trial beneficial effects of patients than GH per se.
In an open study with two different doses of GH,of GH on vitality, energy and overall well-being were
clearly documented by Ma˚rdh et al. [66]. These effects similar effects were obtained with respect to quality of
life after 6 months of therapy, despite a difference inwere sustained after 12 months (table 2). Inconsistent
effects were reported in a study by Beshyah et al. [67]. A IGF-I response [71]. Both regimens were associated with
beneficial effects as assessed by the NHP and the PGWB.major problem with their study was the uneven match of
patients at baseline. The patients allocated to the placebo In summary, although the results of the different trials
have shown some inconsistencies, taken together a posi-group had significantly more health-related problems
than the other group, making comparisons difficult. In tive effect of GH in addition to the beneficial effects of
placebo has been observed, at least in patients with AOthe Amsterdam trial of men with childhood onset disease
[8], only patients with MPHD showed reduced vigour disease. To clarify the full potential of GH replacement
therapy further controlled studies with a longer durationand an increased state of anxiety, attributed to low self-
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are desirable. Also, improved instruments for assessing ment demonstrated beneficial treatment effects. Patients
receiving physiological GH treatment required a year ofthe quality of life in GHD have recently been developed
and validated [72, 73]. Ideally, the patients selected for treatment before demonstrating significant improvement
in memory function. As the differences between the twofuture studies should be those with psychosocial prob-
lems, and patients with a detectable structural brain dam- treatment groups disappeared after 1 year of treatment,
it would appear that supraphysiological treatment merelyage should be evaluated separately.
serves to speed up the recovery of memory performance.
After 1 year of treatment, patients and age-matched con-
trols showed similar scores on these memory parametersGH Replacement and Cognitive Function
(fig. 3). This study demonstrates that the improvement
in memory function after short-term GH replacementThere is only one report on the cognitive effects of
GH replacement in GHD children. In an open study, the continues with long-term GH replacement.
From the studies cited, it may be concluded that cog-intellectual capabilities of 11 children aged between 4 and
18 years were assessed before and after 1 year of GH nitive dysfunction is observed both in patients with IGHD
and those with MPHD. In addition, GH replacementtreatment. At the start of treatment the group’s verbal,
nonverbal, and overall abilities fell within the low average therapy improves cognitive function irrespective of the
age at onset of disease. This could indicate that the cogni-range, and their visual-motor skills were below average.
No improvements from pretest to posttest were found tive impairment may, at least partly, be associated with
a disturbance in neural cell metabolism.[24].
In GHD adults the effects of GH replacement on
cognitive function have been evaluated in several studies
(table 4). In one of the first, patients with CO GHD GH and the Brain – Possible Mechanisms of Action
received native human GH or biosynthetic GH for two
separate 4-week periods [74]. Before and at the end of each Binding sites specific for GH have been demonstrated
in several areas of the central nervous system in varioustreatment period, five cognitive tests were performed. GH
administration was found to improve face recognition, a species, including man [77, 78]. The binding sites are
particularly abundant in the choroid plexus, but a hightest that assesses memory. Degerblad et al. [16] performed
a double-blind cross-over study using synthetic GH and density of GH binding has also been found in the pitu-
itary, the hypothalamus and the hippocampus [77]. Thea placebo for 12 weeks each in a small number of patients.
GH replacement did not result in any improvements in last-mentioned structure is considered to have a central
role in learning and memory, and is a part of the limbicmemory and attention. In an open study in adults with
CO GHD, 6 months of GH treatment was associated system, which is involved in affective behaviour [79].
GH binding in the choroid plexus has been found towith an improvement in the symbol-number association
subtest of the Wechsler Adult Intelligence Scale (WAIS) be mainly attributable to the presence of a binding protein
rather than the full length receptor [80]. It has been sug-[75]. In patients with AO GHD (table 4), the effects of GH
supplementation on psychological parameters, including gested that these binding sites may indicate transport of
GH over the blood-brain barrier into the brain [77]. In-cognition as assessed by a subscale of the HSCL, were
studied by Burman et al. [7]. Compared to placebo, GH deed, subcutaneous administration of physiological doses
of GH to GHD patients has been found to be associatedtreatment was found to significantly improve cognitive
ability, memory in particular. In another long-term GH with an increase in GH in the cerebrospinal fluid (CSF)
[81, 82]. A positive relation between the given dose andsubstitution study, the effects of 2 years of GH replace-
ment therapy on cognitive performance were evaluated the increase in GH in the CSF was observed, indicating
passage of GH into the central nervous system [81] (fig. 4).in male patients with CO GHD [76]. Patients who were
initially given placebo were switched to GH therapy after Treatment with GH has been found to result in a
significant decrease in the dopamine metabolite homo-6 months. After the placebo-controlled phase of the study,
short-term and long-term memory were improved. How- vanillic acid in the CSF, but no change in the metabolites
of serotonin and noradrenaline (HMPG), or in the con-ever, when a distinction was made between patients who
had a normalization of serum IGF-I and patients receiv- centration of b-endorphin [81]. As a group the patients
also showed an increase in the concentration of aspartate,ing supraphysiological GH treatment, it appeared that
only the group receiving supraphysiological GH treat- whereas no effects were found on two other neurotrans-
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Table 4. Summary of studies investigating the effect of GH treatment on cognitive function
Study Ref. Subjects Treatment Test Outcome
Abbott et al. 24 n>11 0.15 U/kg/week Intelligence No effects
1982 (4 girls, 7 boys) for 1 year draw-a-person
open MPHD: 4 visual-motor skill
IGHD: 7
Age: 4–18 years
Almqvist et al. 74 n>5 Treatment for 4 weeks Face recognition CRecognition
1986 (2 females, 3 males) with pituitary-derived letter identification memory
open MPHD: 5 or biosynthetic GH, simple additions (face recognition)
Age: 22–36 years 8 IU 3 times weekly letter rotation
CO letter substitution
Degerblad et al. 16 n>6 Cross-over Verbal learning No effects
1990 (3 females, 3 males) Duration: 12 weeks non-verbal learning
controlled MPHD: 5 0.5–0.6 IU/kg/week reaction time
IGHD: 1 symbol-digit substitution
Age: 20–38 years
CO
Sartorio et al. 75 n>8 (males) 6 months of GH Intelligence CIntellectual capacity
1995 MPHD: 5 treatment draw-a-person
open IGHD: 3 0.5 IU/kg/week
Age: 25–34 years
CO
Burman et al. 7 n>36 1.25 U/m2/day for HSCL: subscale CCognitive ability
1995 (15 females, 21 males) 9 months cognitive complaints
controlled MPHD: all cross-over
Age: 28–57 years
AO
Deijen et al. 76 n>45 (all male) Four parallel groups Iconic memory CMemory
in press MPHD: 29 (random assignment) short-term memory
controlled IGHD: 16 Duration: 104 weeks long-term memory
Age: 19–37 years 1, 2 or 3 IU/m2/day
CO
C>More or better; B>less.
mitter amino acids, glutamate and glycine. In this study The monoamine system is considered to be involved
in mood disorders. The dopamine neurones of the mid-lumbar puncture was performed after 9 months of treat-
ment with GH or placebo in a cross-over design. In an- brain project to many parts of the limbic system, includ-
ing areas known to be associated with alterations inother study, where the CSF was assessed in GHD patients
after 1 month on either GH or placebo, the reduction of mood and cognitive functioning. This could indicate an
important role of dopamine in the CNS. Release ofthe dopamine metabolite after treatment with GH was
confirmed [82]. In addition, b-endorphin was found to dopamine in the area of the nucleus accumbens generates
positive reinforcing feelings [84]. A reduction of thebe increased by GH. The discrepant results may be ex-
plained by the design of the studies or reflect method- CSF level of the dopamine metabolite homovanillic acid,
similar to that observed after treatment with GH, hasological differences. For instance in the last-mentioned
study a steady-state situation with respect to side-effects been found after treatment with tricyclic antidepressants
and monoamine oxidase inhibitors [85]. Such drugs gen-such as arthralgia and muscle stiffness is not likely to have
been attained in the short period of the study. In patients erally affect the turnover of more than one monoamine
metabolite, but the effect of GH seems to be morewith fibromyalgia, increased CSF levels of b-endorphin
have been reported [83]. restricted.
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Fig. 3. Mean scores×SE for iconic (a),
short-term (b; associate learning) and long-
term (c; associate recognition) memory tasks
at baseline (n>45), after 12 (n>45), and after
24 months (n>43) of GH treatment. Dotted
lines indicate a 95% confidence interval of the
mean for the control group (n>41);
* p=0.05 compared to baseline [reprinted
from 76, with kind permission from Elsevier,
Kidlington, UK].
treatment with GH not only serum levels but also CSF
levels of free T4 have been found to be decreased [81],
indicating an increase of T3 to T4 ratio in the brain.
The T3 levels in the CSF were, however, too low to be
adequately assessed, a finding supported by others [93].
A link between well-being and thyroid homeostasis in the
brain is corroborated by a decrease in free thyroxine in
the CSF after successful treatment with electroconvulsive
therapy (ECT) in patients with depression [94].
In summary, treatment with GH affects the thyroxine
concentration and turnover of some important neuro-
transmitters in the brain. These effects are in some re-
Fig. 4. Correlation between the CSF concentration of GH and spects similar to those reported after treatment with anti-
the administered dose of rhGH in 24 adults with GH deficiency. depressive drugs and ECT. The possible relation between
(Reproduced from [81] with the permission of the publisher.) these changes and the positive effects on psychological
functioning remains to be clarified.
The elevated CSF level of aspartate may be of particu-
lar relevance for cognitive functions, since aspartate is a
ligand for the N-methyl-D-aspartate (NMDA) receptor Conclusions
[86, 87]. This receptor has been implicated in long-term
potentiation of synaptic efficacy, a potential mechanism Patients with pituitary insufficiency receiving conven-
tional hormone replacement therapy are found to haveof memory in the hippocampus [87]. Interestingly, injec-
tion of an NMDA receptor antagonist has been reported a suboptimal quality of life and reduced cognitive func-
tions. Psychosocially the patients are disadvantaged withto influence the activity of the central dopamine system
[88]. It might thus be speculated that an effect of GH on respect to their family situation and career development,
at least if the disease has been acquired during childhood.the dopamine turnover could be mediated through the
NMDA receptor. In patients with AO disease a tendency towards a higher
rate of disability pensions has been reported, indicatingOther observations of possible significance for emo-
tions and behaviour are the effects of GH on thyroid a reduced capacity for work.
Several factors may be partly responsible for this poorhormone metabolism. A decrease in the serum concentra-
tion of thyroxine (T4) and an increase in serum triiodothy- outcome. Surgical treatment and/or irradiation of the
precipitating disorder, may cause irreversible brain dam-ronine (T3) are generally found after treatment with GH
[89] and are thought to be mediated by enhanced T4 to age. Inadequate replacement regimens with adrenal and
sex steroids or thyroxine may contribute to negativeT3 conversion. In the brain, minor changes in the local
thyroid homeostasis have been considered to be of clinical changes in emotions, mood and behaviour. In patients
with pituitary insufficiency acquired in childhood, therelevance for mood [90]. The addition of T3 to tricyclic
antidepressants may be beneficial for resolution of a de- effects of a chronic disease during an important period
of life, as well as the influence of a short stature per se,pressive state [91, 92], and was formerly used in patients
refractory to conventional antidepressive therapy. During may be of significance.
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During recent years the importance of GH for main- weight. Her oestrogen medication dose was reduced in
1988. During the same time period she started to experi-taining normal body composition and physical perfor-
mance in adult patients has been increasingly recognized. ence anxiety and nervousness.
In the following years she became increasingly moreThe combined data from hitherto published studies on the
relative impact of GH therapy per se on the psychosocial tired, and her social life was reduced to a minimum. She
had problems in concentrating but continued with hercapacity indicate beneficial effects. In particular energy,
vitality and memory have been found to be improved work although she was constantly worried about making
a serious mistake, as her attention was poor. After workby GH. Whether the reported effects of GH on brain
dopamine and thyroxine are of relevance for these im- she felt exhausted and often went to bed after preparing
dinner for her family. Her work took all her strength andprovements remains to be established. Future studies of
longer duration, with improved instruments, and with she finally changed, after much hesitation and consider-
able grief, to a less demanding position as a nurse in ahomogeneous groups of patients without significant
structural brain damage, should clarify the full potential municipal nursing home for the elderly. During these
difficult years she discussed her situation with her districtof GH replacement therapy on the capacity for work and
the quality of life. medical officer, and an antidepressant drug was tried but
without any positive effects.
In 1990 2 of her 4 sisters passed away. This was aPatient Account
This report is based on the patient’s own written report serious blow and worsened her condition. She was now
convinced that she had acquired some unusual mentalof how she describes herself, how she experienced her
pituitary disease and the medication she was given, in disorder and reduced her working time from 75 to 50%.
In the same year she was asked if she would take partparticular GH.
The patient is a previously healthy nurse, born in 1947, in a placebo-controlled study of GH. Placebo and GH
would be given in random order for 9 months each.who at the beginning of the seventies gradually developed
headache, irregular bleedings, loss of weight, marked This offer was experienced as ‘a light in the tunnel’,
although no promises of an improved situation weretiredness, thinning of the scalp hair and intermittent bouts
of fainting. She was given medication for migraine with- made.
After a few weeks on the first ‘drug’ (which was laterout effect. Her fainting fits became more frequent and
she seeked medical care several times at the local hospital. found to be GH), she and her family and her colleagues
noticed a change for the better. Slowly but steadily sheLumbar puncture and brain scintigraphy were reported
to be normal. After approximately 4 years since the onset began to return to her former self, i.e. a creative, happy
and extroverted person. At her new job she had previouslyof the first symptoms she was admitted for a thyroid
scan which revealed a low iodine uptake. Laboratory tests been perceived as shy and quiet, a person who did her
job and then returned home. With time she regained hershowed low levels of serum cortisol. A diagnosis of hypo-
pituitarism was made, and an empty sella was found on X- physical capacity and she took up her previous interest
in swimming and long walks. ‘I felt like a machine thatray investigations. During this period she had undergone
further training in intensive care. She was on sick-leave finally had been given the right kind of petrol’, the patient
told us.for short periods. After the start of replacement therapy
with thyroxine, corticosteroids and oestrogen, she worked She has now been on treatment with GH for 6 years.
She worked full time for a year without problems, but65% and felt well.
As she and her husband wanted to have children, ovu- has now returned to 75% and is studying at the university
in parallel with her work at the nursing home, which shelation was induced by gonadotrophins. The treatment
was successful regarding ovulation, but was associated is now quite content with.
The patient summarises her story with the followingwith severe headache, and was stopped at the request
of the patient after three courses of gonadotrophins that statements: For me treatment with GH gave me my per-
sonality back. It gave my husband his wife back. It gavedid not result in pregnancy. The couple then decided to
adopt children and received 2 boys in 1979 and 1981, my 2 boys a mother they need and are entitled to. It gave
my friends once more a person who takes the time torespectively.
In 1987, at the age of 40, the patient started to work listen to them and support them if needed. I live a normal
life and most people around me are not aware of my75% as a nurse in a renal dialysis unit. The new tasks
were perceived as stressful and demanding and she lost disorder, which must be considered a good sign.
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